OR WAIT null SECS
Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.
November 06, 2015
Even though rising production and use of generic pharmaceuticals is saving billions for the nation’s healthcare system, policy makers continue to slap the industry with policies it claims will limit product development and sales.
November 02, 2015
New program emphasizes quality, risk, and global collaboration.
October 27, 2015
Despite considerable investment by biotech manufacturers in developing competitive biologics for the US market, gaining FDA approval of these products has turned out to be a slow and complex process.
September 22, 2015
In testifying before Congress on FDA regulation of long-awaited biosimilars, Janet Woodcock emphasized the importance of ensuring that the evaluation of new therapies is based on sound science.
September 16, 2015
The White House nominates Robert Califf to head FDA, but will he be confirmed?
September 15, 2015
Manufacturers challenge details in new policies designed to promote access to important therapies.